Capricor Therapeutics (CAPR) Could Be 89% Undervalued Following Deramiocel And Loss Concerns
Capricor Therapeutics (CAPR) is back in focus after reporting second quarter 2026 results and wider losses, alongside ongoing legal and regulatory questions around its lead Duchenne muscular dystrophy candidate, Deramiocel.
See our latest analysis for Capricor Therapeutics.
The latest Q2 loss and ongoing Deramiocel scrutiny have come alongside sharp volatility in Capricor Therapeutics’ stock, with the share price jumping 58% in the last day and 73% over seven days, yet still down strongly year to date and with long term total shareholder returns appearing far smoother by comparison.
If recent regulatory headlines have you reassessing biotech risk, this can be a good moment to broaden your search and check out 41 healthcare AI stocks
Capricor Therapeutics now sits at the intersection of a high risk lead asset and a sharply rebounding share price. After such a fast move, does the current market value still leave enough room for error on Deramiocel and the lawsuits?
Most Popular Narrative: 88.5% Undervalued
Capricor Therapeutics last closed at $6.65, while the most followed narrative on the stock assigns a fair value of $58. This gap frames a very different picture to the recent price swings.
The most compelling reason to look at Capricor right now is that Deramiocel is just the tip of the iceberg. An FDA approval functionally validates the therapeutic viability of the company''s underlying exosome platform. Capricor is already leveraging this momentum to develop StealthX, a next-generation engineered exosome platform capable of carrying specific tissue-targeted genetic payloads, spanning from vaccines to oncological therapeutics.
Want to understand why this narrative sees so much upside in Capricor Therapeutics. The fair value hangs on ambitious revenue ramps, shifting profit margins and a future earnings profile more often linked with mature commercial biotech platforms.
Result: Fair Value of $58 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this bullish Capricor Therapeutics narrative could be challenged if the NS Pharma dispute escalates or if regulators take a tougher stance on Deramiocel.
Find out about the key risks to this Capricor Therapeutics narrative.
Next Steps
Given the mix of optimism and concern around Capricor Therapeutics, it makes sense to review the full picture yourself and move quickly to shape your own view by weighing up the 2 key rewards and 3 important warning signs.
Looking for more investment ideas beyond Capricor Therapeutics?
Do not wait for the next headline to start broadening your watchlist. Use the Simply Wall St screener now to spot opportunities that better fit your goals.
- Pinpoint potential bargains by scanning companies that currently screen as 52 high quality undervalued stocks.
- Strengthen your focus on financial resilience by checking out the solid balance sheet and fundamentals stocks screener (50 results).
- Get ahead of the crowd by reviewing the screener containing 19 high quality undiscovered gems before more investors catch on.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com